Alaunos Therapeutics (TCRT) Operating Expenses (2009 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Alaunos Therapeutics was $4.06 million, up 0.5% year-over-year; for FY2025, it was $4.23 million, down 12.3% from FY2024.

• Annual Operating Expenses has declined for five consecutive years, with a five-year compound annual growth rate of -44.5% (FY2020 to FY2025).
• In prior years, Alaunos Therapeutics' Operating Expenses was $4.82 million in FY2024 (-85.9%), $34.27 million in FY2023 (-9.9%), $38.03 million in FY2022 (-51.2%) and $77.95 million in FY2021 (-3.0%).
• Quarterly Operating Expenses has run from a low of $759,000 in Q4 2024 to a high of $22.69 million in Q3 2021 over five years.
• On a year-over-year basis, Operating Expenses increased in two of the last eight quarters, with an average decline of 27.3%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2025, with growth of 19.9%; the weakest was Q4 2024, with a decline of 90.5%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $1.01 million (Q1 2026), $910,000 (Q4 2025) and $1.19 million (Q3 2025).